CAR-T Trial Raises Prospect of Preventing Myeloma in High-Risk Group

(MedPage Today) — SAN DIEGO — Ciltacabtagene autoleucel (cilta-cel, Carvykti) as primary therapy induced deep and durable responses in every patient in a small phase II trial in high-risk latent multiple myeloma, a precursor to active multiple myeloma…